LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Markets' 9th Annual Best Ideas Growth (BIG9) Conference on Thursday, September 11, 2025.
Biodesix recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer Biodesix recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer
Biodesix, Inc. (NASDAQ:BDSX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Robin Harper Cowie - CFO, Secretary & Treasurer Scott Hutton - President, CEO & Director Conference Call Participants Alexander Davis Vukasin - Canaccord Genuity Corp., Research Division Andrew Frederick Brackmann - William Blair & Company L.L.C., Research Division Thomas Flaten - Lake ...
Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo.
BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025.
LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2025 after the close of trading on Thursday, August 7. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business u...
Nation's first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs Nation's first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs
LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.